Trials / Completed
CompletedNCT00112294
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab Versus Taxane/Carboplatin as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 755 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel (Taxane) | IV, 225 mg/m\^2 |
| DRUG | Docetaxel (Taxane) | IV, 75 mg/m\^2 |
| DRUG | Carboplatin | AUC=6, q 3 weeks (6 cycles maximum) |
| DRUG | Cetuximab | Intravenous, 400 mg/m\^2, initial dose followed by 250 mg/m\^2, weekly starting on Week 2 |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2007-04-01
- Completion
- 2008-08-01
- First posted
- 2005-06-02
- Last updated
- 2015-12-24
- Results posted
- 2010-10-05
Locations
124 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00112294. Inclusion in this directory is not an endorsement.